Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
124.51
+2.10 (1.72%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for SRPT stock have an average target of 186.21, with a low estimate of 109 and a high estimate of 235. The average target predicts an increase of 49.55% from the current stock price of 124.51.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SRPT stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 7 | 9 | 10 | 11 | 11 | 12 |
| Hold | 4 | 4 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 18 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $150 | Buy | Initiates | $150 | +20.47% | Oct 10, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $181 → $182 | Buy | Maintains | $181 → $182 | +46.17% | Oct 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $152 | Hold | Reiterates | $152 | +22.08% | Sep 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $181 | Buy | Reiterates | $181 | +45.37% | Sep 19, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $181 | Buy | Reiterates | $181 | +45.37% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
1.78B
from 1.24B
Increased by 43.08%
Revenue Next Year
3.19B
from 1.78B
Increased by 79.43%
EPS This Year
1.62
from -5.80
EPS Next Year
11.46
from 1.62
Increased by 607.01%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.0B | 3.8B | 4.6B | ||
| Avg | 1.8B | 3.2B | 3.8B | ||
| Low | 1.5B | 2.6B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 63.0% | 111.0% | 42.6% | ||
| Avg | 43.1% | 79.4% | 17.9% | ||
| Low | 17.6% | 48.8% | -47.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.39 | 17.35 | 20.32 | ||
| Avg | 1.62 | 11.46 | 14.45 | ||
| Low | 0.26 | 7.17 | 8.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 970.4% | 77.3% | ||
| Avg | - | 607.0% | 26.1% | ||
| Low | - | 342.7% | -27.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.